BioAgilytix Makes Multi-Million-Dollar Investments in LC/MS Capabilities

Officials at BioAgilytix say the company has advanced its growth strategy with multi-million-dollar investments in liquid chromatography–mass spectrometry (LC/MS) capabilities, including new platforms and expanded lab space in Hamburg, Germany, and Durham, NC.

BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS. Combining LC/MS and ligand binding assay (LBA) services allows BioAgilytix to provide solutions for complex programs, including antibody-drug conjugates (ADCs), peptides, oligonucleotides, large and small molecules, according to Dave Beyerlein, global lead for LC/MS.

Dedicated GxP and GMP labs across multiple sites support both non-regulated exploratory studies and regulated bioanalysis aligned with international health authority standards, he points out.

“LC/MS is critical to supporting the most innovative therapeutics,” says Beyerlein. “By harmonizing our platforms and processes, we ensure that our customers can move assays efficiently between sites and trust that the same standards of excellence are maintained across regions, [including Australia].”